About UCSF Search UCSF UCSF Medical Center

Nola M. Hylton, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
hylton_nola

Professor in Residence, Department of Radiology, UCSF; and Director, Magnetic Resonance Science Center

Nola.Hylton@radiology.ucsf.edu

Phone: (415) 476-8856, 476-9023 (voice)
Box 1290, UCSF
San Francisco, CA 94143-1290

View on UCSF Profiles


Education

Massachusetts Institute of Technology (M.I.T.), B.S., 1979, Chemical Engineering
Stanford University, Ph.D., 1985, Applied Physics

Professional Experience

  • 6/76-8/76
    Technical Associate, Bell Telephone Laboratories, Murray Hill, N.J.
  • 6/77-8/77
    Research Assistant, Bell Telephone Laboratories, Murray Hill, N.J.
  • 6/78-8/78
    Research Assistant, Bell Telephone Laboratories, Murray Hill, N.J.
  • 9/79-12/82
    Research Assistant, E. L. Ginzton Laboratory, Stanford University, Stanford,California
  • 1/83-12/84
    Research Assistant, Radiologic Imaging Laboratory, Department of Radiology, University of California, San Francisco
  • 1/85-7/92
    Assistant Professor, Radiologic Imaging Laboratory, Department of Radiology, University of California, San Francisco
  • 7/90-9/97
    Faculty Member, Graduate Group in Biophysics, University of California, San Francisco
  • 7/92-6/95
    Assistant Professor, Magnetic Resonance Science Center, Department of Radiology, University of California, San Francisco
  • 7/95-6/02
    Associate Adjunct Professor, Magnetic Resonance Science Center, Department of Radiology, University of California, San Francisco
  • 9/97-present
    Faculty Member, Bioengineering Graduate Group, University of California, San Francisco and University of California, Berkeley
  • 1/98-present
    Faculty Member, Breast Oncology Program, UCSF Cancer Center
  • 7/02-present
    Professor in Residence, Magnetic Resonance Science Center, Department of Radiology, University of California, San Francisco
  • 2/04-present
    Director, Magnetic Resonance Science Center, Dept. of Radiology, UCSF

Selected Publications

  1. Elias SG, Adams A, Wisner DJ, Esserman LJ, van't Veer LJ, Mali WP, Gilhuijs KG, Hylton NM. Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014 Aug; 23(8):1464-83.
    View on PubMed
  2. Aliu SO, Jones EF, Azziz A, Kornak J, Wilmes LJ, Newitt DC, Suzuki SA, Klifa C, Gibbs J, Proctor EC, Joe BN, Hylton NM. Repeatability of quantitative MRI measurements in normal breast tissue. Transl Oncol. 2014 Feb; 7(1):130-7.
    View on PubMed
  3. Chenevert TL, Malyarenko DI, Newitt D, Li X, Jayatilake M, Tudorica A, Fedorov A, Kikinis R, Liu TT, Muzi M, Oborski MJ, Laymon CM, Li X, Thomas Y, Jayashree KC, Mountz JM, Kinahan PE, Rubin DL, Fennessy F, Huang W, Hylton N, Ross BD. Errors in Quantitative Image Analysis due to Platform-Dependent Image Scaling. Transl Oncol. 2014 Feb; 7(1):65-71.
    View on PubMed
  4. Boes JL, Hoff BA, Hylton N, Pickles MD, Turnbull LW, Schott AF, Rehemtulla A, Chamberlain R, Lemasson B, Chenevert TL, Galb N CJ, Meyer CR, Ross BD. Image registration for quantitative parametric response mapping of cancer treatment response. Transl Oncol. 2014 Feb; 7(1):101-10.
    View on PubMed
  5. Newitt DC, Aliu SO, Witcomb N, Sela G, Kornak J, Esserman L, Hylton NM. Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform. Transl Oncol. 2014 Feb; 7(1):94-100.
    View on PubMed
  6. Jafri NF, Newitt DC, Kornak J, Esserman LJ, Joe BN, Hylton NM. Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy. J Magn Reson Imaging. 2014 Aug; 40(2):476-82.
    View on PubMed
  7. Wang J, Azziz A, Fan B, Malkov S, Klifa C, Newitt D, Yitta S, Hylton N, Kerlikowske K, Shepherd JA. Agreement of mammographic measures of volumetric breast density to MRI. PLoS One. 2013; 8(12):e81653.
    View on PubMed
  8. Wisner DJ, Rogers N, Deshpande VS, Newitt DN, Laub GA, Porter DA, Kornak J, Joe BN, Hylton NM. High-resolution diffusion-weighted imaging for the separation of benign from malignant BI-RADS 4/5 lesions found on breast MRI at 3T. J Magn Reson Imaging. 2014 Sep; 40(3):674-81.
    View on PubMed
  9. Wisner DJ, Hwang ES, Chang CB, Tso HH, Joe BN, Lessing JN, Lu Y, Hylton NM. Features of Occult Invasion in Biopsy-Proven DCIS at Breast MRI. Breast J. 2013 Nov; 19(6):650-8.
    View on PubMed
  10. McLaughlin RL, Newitt DC, Wilmes LJ, Jones EF, Wisner DJ, Kornak J, Proctor E, Joe BN, Hylton NM. High resolution in vivo characterization of apparent diffusion coefficient at the tumor-stromal boundary of breast carcinomas: A pilot study to assess treatment response using proximity-dependent diffusion-weighted imaging. J Magn Reson Imaging. 2014 May; 39(5):1308-13.
    View on PubMed
  11. Dorgan JF, Klifa C, Deshmukh S, Egleston BL, Shepherd JA, Kwiterovich PO, Van Horn L, Snetselaar LG, Stevens VJ, Robson AM, Lasser NL, Hylton NM. Menstrual and reproductive characteristics and breast density in young women. Cancer Causes Control. 2013 Nov; 24(11):1973-83.
    View on PubMed
  12. Ojeda-Fournier H, de Guzman J, Hylton N. Breast magnetic resonance imaging for monitoring response to therapy. Magn Reson Imaging Clin N Am. 2013 Aug; 21(3):533-46.
    View on PubMed
  13. Bolouri MS, Elias SG, Wisner DJ, Behr SC, Hawkins RA, Suzuki SA, Banfield KS, Joe BN, Hylton NM. Triple-negative and non-triple-negative invasive breast cancer: association between MR and fluorine 18 fluorodeoxyglucose PET imaging. Radiology. 2013 Nov; 269(2):354-61.
    View on PubMed
  14. Mukhtar RA, Yau C, Rosen M, Tandon VJ. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol. 2013 Nov; 20(12):3823-30.
    View on PubMed
  15. Yitta S, Joe BN, Wisner DJ, Price ER, Hylton NM. Recognizing artifacts and optimizing breast MRI at 1.5 and 3 T. AJR Am J Roentgenol. 2013 Jun; 200(6):W673-82.
    View on PubMed
  16. Lehman CD, Blume JD, DeMartini WB, Hylton NM, Herman B, Schnall MD. Accuracy and interpretation time of computer-aided detection among novice and experienced breast MRI readers. AJR Am J Roentgenol. 2013 Jun; 200(6):W683-9.
    View on PubMed
  17. Mahoney ME, Gordon EJ, Rao JY, Jin Y, Hylton N, Love SM. Intraductal therapy of ductal carcinoma in situ: a presurgery study. Clin Breast Cancer. 2013 Aug; 13(4):280-6.
    View on PubMed
  18. Jones EF, Sinha SP, Newitt DC, Klifa C, Kornak J, Park CC, Hylton NM. MRI enhancement in stromal tissue surrounding breast tumors: association with recurrence free survival following neoadjuvant chemotherapy. PLoS One. 2013; 8(5):e61969.
    View on PubMed
  19. Wilmes LJ, McLaughlin RL, Newitt DC, Singer L, Sinha SP, Proctor E, Wisner DJ, Saritas EU, Kornak J, Shankaranarayanan A, Banerjee S, Jones EF, Joe BN, Hylton NM. High-resolution diffusion-weighted imaging for monitoring breast cancer treatment response. Acad Radiol. 2013 May; 20(5):581-9.
    View on PubMed
  20. De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F, Meszoely IM, Nanda R, Hwang ES. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer. 2013 May 15; 119(10):1776-83.
    View on PubMed

Go to UCSF Profiles, powered by CTSI